Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATZUMI vs VALTOCO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.
GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults with PD-L1 expression ≥50%, with no EGFR or ALK genomic aberrations,First-line treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide,First-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations, in combination with bevacizumab, paclitaxel, and carboplatin,First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and carboplatin,Treatment of locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy, or in cisplatin-ineligible patients with PD-L1 expression,Treatment of metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient mismatch repair (d MMR) after prior fluoropyrimidine, oxaliplatin, and irinotecan therapy,Off-label uses: Various solid tumors with PD-L1 expression or MSI-H/d MMR
Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy aged 2 years and older
1.2 g intravenously every 12 hours over 10-12 hours.
5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.
Terminal elimination half-life is 12-15 hours in patients with normal renal function (Cr Cl >90 m L/min), allowing once-daily dosing. Renal impairment prolongs half-life (up to 30 hours in Cr Cl 30-50 m L/min).
Terminal elimination half-life: 15-17 hours (range 11-20 h) in adults; no dose adjustment for age or renal impairment is recommended, but clinical monitoring is prudent in hepatic impairment.
Metabolized via catabolic pathways into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Hepatic via CYP3A4 and CYP2C9; active metabolite desmethyldiazepam (nordazepam)
Approximately 70% of the dose is excreted renally as unchanged drug; 20% is eliminated via biliary/fecal routes as metabolites, with <5% as unchanged drug in feces.
Renal (70% as unchanged drug and metabolites, primarily glucuronide conjugate, with <2% as unchanged drug); biliary/fecal (30%)
95% bound to albumin and alpha-1-acid glycoprotein; binding is saturable at high concentrations.
96% bound, primarily to albumin
2.5-3.5 L/kg, indicating extensive extravascular distribution (e.g., tissues, erythrocytes).
0.5-0.8 L/kg; approximates total body water, indicating extensive tissue distribution.
Oral: 70-80% (first-pass metabolism reduces bioavailability; food increases absorption by 15%).
Intranasal: 75% (range 65-85%) relative to intravenous; rectal: 70-90% relative to intravenous.
Cr Cl 30-60 m L/min: 1.2 g every 18 hours; Cr Cl 10-29 m L/min: 1.2 g every 24 hours; Cr Cl <10 m L/min: 1.2 g loading dose then 0.6 g every 24 hours.
No dosage adjustment required for mild to moderate renal impairment. Severe renal impairment (e GFR <15 m L/min): consider using lower doses due to increased exposure; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Child-Pugh A or B: no adjustment needed. Child-Pugh C: reduce dose by 50% due to increased diazepam exposure.
Not approved for pediatric patients under 18 years.
Age 6-17 years: 0.2 mg/kg intranasally, maximum single dose 20 mg. Administer as single dose per seizure cluster. Not recommended for children <6 years.
No specific dose adjustment required; monitor renal function.
Elderly patients may have increased sensitivity; consider starting at lower end of dosing range (5-10 mg) and titrate based on response and tolerability. Use with caution due to risk of sedation and falls.
None.
WARNING: RISK OF RESPIRATORY DEPRESSION AND CARDIAC ARREST WITH CONCOMITANT USE OF ALCOHOL OR OTHER CNS DEPRESSANTS; RISK OF SUBSTANCE ABUSE, DEPENDENCE, AND WITHDRAWAL; WITHDRAWAL SEIZURES; AND RISK OF SERIOUS SKIN REACTIONS.
Immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin adverse reactions,Infusion-related reactions,Embryofetal toxicity,Increased risk of severe or fatal infection,Use caution in patients with autoimmune disease or organ transplant
Risk of CNS depression and impaired motor function,Risk of abuse and dependence,Risk of withdrawal seizures upon abrupt discontinuation,Risk of serious skin reactions (e.g., Stevens-Johnson syndrome),Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death,Use in patients with compromised respiratory function or hepatic impairment requires caution
Severe hypersensitivity to atzumi or any excipients,Active severe autoimmune disease requiring systemic immunosuppression (relative),Pregnancy (embryofetal toxicity)
Hypersensitivity to diazepam or any component of the formulation,Acute narrow-angle glaucoma,Concomitant use with opioid analgesics for acute treatment of seizure clusters (unless alternative treatments are not available)
Avoid alcohol consumption during therapy and for 48 hours after last dose due to risk of disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions known.
No specific food interactions. Avoid alcohol consumption during VALTOCO use as it may increase CNS depressant effects.
Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avoid unless benefit outweighs risk.
Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used chronically. Second and third trimesters: May cause fetal benzodiazepine exposure leading to floppy infant syndrome, neonatal withdrawal, and central nervous system depression. Late third trimester or delivery: Risk of neonatal respiratory depression, hypotonia, and feeding difficulties.
No data on excretion in human milk; M/P ratio unknown. Caution advised; use only if clearly needed.
Diazepam is excreted into breast milk with an M/P ratio approximately 0.3. The relative infant dose is low (2-5% of weight-adjusted maternal dose). Caution is advised due to potential accumulation in neonates (long half-life) causing sedation, poor feeding, and respiratory depression. Use only if clearly needed with infant monitoring.
No established dosing adjustments; pharmacokinetic changes in pregnancy may alter exposure. Monitor therapeutic response and adjust dose empirically based on clinical efficacy and toxicity.
No specific dose adjustment recommended for VALTOCO during pregnancy for acute seizure management. However, due to increased volume of distribution and altered protein binding in pregnancy, a higher dose or more frequent dosing may be required for chronic use; clinical response should guide titration. Monitor for excessive sedation or respiratory depression as clearance may be reduced in late pregnancy.
ATZUMI (aztreonam) is a monobactam antibiotic with activity against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. It is often used in patients with severe beta-lactam allergies (e.g., anaphylaxis to penicillins) due to minimal cross-reactivity. Monitor renal function (creatinine clearance) as dose adjustment is required in renal impairment. For cystic fibrosis patients, higher doses or continuous infusion may be considered. Administer over 20-60 minutes to reduce infusion-related phlebitis. Note: Inhaled aztreonam lysine (not ATZUMI) is used for chronic pulmonary infections in cystic fibrosis.
VALTOCO (diazepam nasal spray) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients with epilepsy aged 6 years and older. Administer one spray into one nostril; if needed, a second spray into the opposite nostril can be given after 4 hours if seizure activity persists. Do not use more than two doses per episode. Onset of action is rapid (within 2-5 minutes). Monitor for respiratory depression, especially in patients with compromised respiratory function or concomitant CNS depressants. Each spray delivers 5 mg or 10 mg diazepam; the dose depends on patient weight (5 mg for <40 kg, 10 mg for ≥40 kg). Tilt patient's head back slightly during administration. Do not reuse the device; discard after use.
Take this medication exactly as prescribed; do not skip doses or stop early unless instructed.,Report any signs of allergic reaction (rash, hives, itching, difficulty breathing, swelling of face/tongue) immediately.,Infusion site reactions (redness, swelling, pain) are common; notify healthcare provider if severe.,This drug may cause diarrhea, especially if prolonged; contact your doctor if watery or bloody stools occur.,Avoid alcohol while on this medication to reduce risk of disulfiram-like reaction (nausea, vomiting, headache).,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Complete full course even if you feel better to prevent antibiotic resistance.
Use VALTOCO exactly as prescribed; only for seizure clusters, not for daily seizures.,Administer one spray into one nostril; do not prime the device.,After administration, tilt head back slightly and breathe normally.,If seizure activity continues after 4 hours, a second dose may be given in the opposite nostril.,Do not use more than two doses per seizure episode; if ineffective, seek emergency medical help.,Store at room temperature (20-25°C); protect from light and moisture.,Keep out of reach of children; discard device after use.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects wear off.,Inform healthcare provider of all medications, especially CNS depressants (e.g., alcohol, opioids, sedatives).,Do not consume alcohol while using VALTOCO.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATZUMI vs VALTOCO, answered by our medical review team.
ATZUMI is a Benzodiazepine Anticonvulsant that works by Atzumi is a monoclonal antibody that binds to the programmed death-ligand 1 (PD-L1) receptor, blocking its interaction with PD-1 and CD80, thereby restoring anti-tumor T-cell activity.. VALTOCO is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATZUMI and VALTOCO depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATZUMI is: 1.2 g intravenously every 12 hours over 10-12 hours.. The standard adult dose of VALTOCO is: 5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATZUMI and VALTOCO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATZUMI is classified as Category C. Insufficient human data; animal studies show embryotoxicity at maternal toxic doses. First trimester: potential risk based on animal data. Second/third trimester: limited data; avo. VALTOCO is classified as Category C. Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.